menu
    • menu
    [{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmascience Inc. \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmascience Inc. \/ Not Applicable"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pharmascience Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."},{"orgOrder":0,"company":"Pharmascience Inc.","sponsor":"Pharmascience Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Beta tubulin polymerisation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Pharmascience Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Pharmascience Inc. \/ Pharmascience Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Pharmascience Inc. \/ Pharmascience Inc."}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmascience Inc.

    Menu

    Pharmascience Inc.

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmascience Inc.

                            Canada arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmascience Canada is Thrilled to Launch (PR)pms-Teriflunomide

                            Details : Aubagio-Generic (teriflunomide) is an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase. It is indicated for the treatment of patients with relapsing remitting multiple sclerosis.

                            Product Name : pms-Teriflunomide

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 27, 2022

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmascience Introduces Myinfla(TM) (Colchicine 0.5 Mg Extended-Release Tablets), a New Repurposed Treatment ...

                            Details : Myinfla (colchicine 0.5 mg extended-release tablets) inhibits the Beta tubulin polymerisation, which is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease.

                            Product Name : Myinfla

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 22, 2021

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Colchicine Reduces the Risk of COVID-19-related Complications

                            Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                            Product Name : Myinfla

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 23, 2021

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Colchicine Shows Promise as a Treatment for at-home COVID-19 Patients

                            Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                            Product Name : Myinfla

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 29, 2020

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmascience Reiterates Its Support to the Montreal Heart Institute's Colchicine Repurposing Research Studies...

                            Details : The first of these sub analyses simultaneously published in the European Heart Journal reveals that early initiation of low-dose colchicine within the first 3 days after MI significantly reduces the risk of ischemic CV events by 48% as vs placebo on top ...

                            Product Name : Myinfla

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            August 31, 2020

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed

                            Pharmascience Inc.

                            Canada arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Montreal Heart Institute Announces COLCORONA Trial in Patients with COVID-19 Passes Futility Test in Interim A...

                            Details : Colchicine tablets inhibits the beta tubulin polymerisation, which is investigated for the treatment of COVID-19 infection in non-hospitalized patients.

                            Product Name : Myinfla

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 30, 2020

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Montreal Heart Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth